EN DE
Watch Humacyte Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Humacyte Inc (HUMA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Humacyte Inc stock $0.30, price $0.59, that is 49.4% below the price, quality 30 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

HI Humacyte Inc logo Thin data Nov 10, 2026

Humacyte Inc

HUMA · US
Very expensive, weak quality

Our calculation puts a fair price 49% below what the stock costs today.

Revenue last quarter +35% vs. a year ago.
Mixed Growth (revenue 5y +6.4 %/yr in USD)
Insiders bought $89,990 (6M) · sold $82,597
Fair value $0.2987 · Strongly overvalued
Quality 30/100
High debt
Negative free cash flow
Trails peers (1/7)
Narrow moat 30/100 · thin data
Thin data
Estimate
Watch Humacyte Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$16.99 $0.3540 Fair Value $0.2987 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.3540 – $16.99 · fair‑value band $0.2240 – $0.3733 · the $0.5900 price screens above the $0.2987 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Humacyte in your weekly email

Every Wednesday you see whether Humacyte is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

Show moreShow less

The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.

Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Stock analysis

Humacyte Inc (HUMA) currently trades at $0.5900, while our estimate is $0.2987, 49% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.2240 (bear) to $0.3733 (bull), the price of $0.5900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Humacyte Inc reported revenue of $2.0M in FY2025 versus $1.3M in FY2021, a compound +12.7%/yr. Reported net income was −$40.8M in FY2025.

Key figures

Market cap $138M Micro · P/S ratio 51.8 · EPS (TTM) $−0.5100 · Return on equity −548% · Return on assets (EBIT) −64.6% (5-year average) · Operating margin −6,649% · Revenue (TTM) $2.1M · Revenue growth (YoY) +34.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 60% below its 52-week high and 67% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −49%, HUMA screens richer than that median.

Fair Value

Bear $0.2240 Fair Value $0.2987 Bull $0.3733
Price $0.5900 · Downside -49.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 79
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 25
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 12
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors bought shares worth $89,990, most recently on Sep 14, 2026. Over the same period, 2 people sold shares worth $82,597. Buying cluster

  • BuyKeith Anthony JonesDirector3× since Aug 17, 2026: 50,000 shares, avg. $0.6040$30,200Sep 14, 2026
  • BuyKathleen SebeliusDirector56,818 shares at $0.8800$50,000May 19, 2026
  • BuyMichael T. ConstantinoDirector11,000 shares at $0.8900$9,790May 18, 2026
  • SaleDale A. SanderCFO and Chief Corp. Dev. Off45,887 shares at $0.9000$41,298May 18, 202610b5-1 plan
  • SaleShamik J ParikhChief Medical Officer45,887 shares at $0.9000$41,298May 18, 202610b5-1 plan

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 9/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,332.7% (2020) → −5,271.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

HUMA screens overvalued: fair value 49% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Humacyte Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −49.4% · Bottom 25%
Profitability
Return on assets −35.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 34.9% · Top 25%
Balance sheet
Debt / equity 11.40× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 44.44× · Priciest 25%
P/S (12 months) 65.14× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs HUMA
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs HUMA
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs HUMA
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs HUMA
argenx SE ARGX $971.55 $908.40 −7% vs HUMA
CSL Limited CSL A$201.68 A$181.40 −10% vs HUMA
Moderna, Inc MRNA $250.83 $158.70 −37% vs HUMA
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs HUMA
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs HUMA
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs HUMA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Humacyte Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Humacyte Inc Fair Value". https://www.fairvalue-calculator.com/stock/HUMA

Frequently asked questions

Is Humacyte Inc (HUMA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.2987 versus a price of $0.5900, about 49% lower (overvalued).
What is the fair value of HUMA?
Our estimate for Humacyte Inc is $0.2987 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.5900.
What is the quality score of HUMA?
Humacyte Inc has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Humacyte Inc (HUMA)?
Our calculated price target is the estimate of $0.2987 (as of Nov 10, 2026). Cautious scenario $0.2240, optimistic scenario $0.3733. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Humacyte Inc stock forecast for 2026?
Our estimate puts fair value at $0.2987, about 49% lower versus a price of $0.5900 (overvalued). Cautious scenario $0.2240, optimistic scenario $0.3733. The calculation is refreshed regularly with new filings.
What is the revenue of Humacyte Inc (HUMA)?
Humacyte Inc reported trailing-twelve-month revenue of about $2.1M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Humacyte Inc (HUMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Humacyte Inc it is $0.2987 per share (as of Nov 10, 2026), against a price of $0.5900.
Is Humacyte Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, HUMA trades above its calculated fair value: price $0.5900, fair value $0.2987, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HUMA?
No. The price is what the market pays today ($0.5900); the fair value is what the company's own numbers justify ($0.2987). For Humacyte Inc the two are $0.2913 per share apart. That gap is exactly why we show both numbers side by side.
How much is Humacyte Inc worth?
The market values Humacyte Inc at about $138M (market capitalisation, as of Nov 10, 2026). Per share that is $0.5900; our models calculate a fair value of $0.2987 per share.
What do the bullish and bearish scenarios say about HUMA?
Our models span a range for Humacyte Inc: cautious scenario $0.2240, base $0.2987, optimistic $0.3733 per share (as of Nov 10, 2026, price $0.5900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Humacyte Inc (HUMA)?
Balance-sheet figures for Humacyte Inc (as of Nov 10, 2026): debt of 11.40 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is HUMA from its 52-week high?
Humacyte Inc trades at $0.5900, about 60% below its 52-week high of $1.49 and 67% above the low of $0.3540 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2987 is for.
Which stocks are comparable to Humacyte Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Humacyte Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.5900, calculated fair value $0.2987 (−49%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Humacyte Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Humacyte Inc (HUMA)?
The closing price on Nov 10, 2026 was $0.5900. Our estimate is $0.2987, about 49% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Humacyte Inc right now?
The price sits above even our optimistic bull case ($0.3733). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Humacyte Inc

How large is the market capitalisation of Humacyte Inc (HUMA)?
The market capitalisation of Humacyte Inc is $138M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Humacyte Inc (HUMA)?
The price-to-sales ratio of Humacyte Inc is 51.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Humacyte Inc (HUMA)?
Earnings per share at Humacyte Inc are $−0.5100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Humacyte Inc (HUMA)?
The return on equity (ROE) of Humacyte Inc is −548% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Humacyte Inc (HUMA)?
On an EBIT basis the return on assets of Humacyte Inc is −64.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Humacyte Inc (HUMA)?
The operating margin of Humacyte Inc is −6,649% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Humacyte Inc (HUMA)?
Revenue at Humacyte Inc is growing +34.9% versus a year earlier (3y avg +9.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Humacyte Inc (HUMA) generate?
The free cash flow of Humacyte Inc is −$106M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Humacyte Inc (HUMA) carry?
The net debt of Humacyte Inc is $14.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Humacyte Inc in the live analysis

One click puts Humacyte Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.